| Symbol | CLVLY |
|---|---|
| Name | CLINUVEL PHARMACEUTICALS LTD. |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 3000 Australia VA Level 11, 535 Bourke Street |
| Telephone | +61 3 9660 4900 |
| Fax | — |
| — | |
| Website | http://www.clinuvel.com |
| Incorporation | AU |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | 0001290877 |
| Description | Clinuvel Pharmaceuticals Ltd is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With our unique expertise in understanding the interaction of light and human skin, we have identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from 10,000 to 45 million. Additional info from OTC: |
Controlled-release injectable peptide platform evaluated in preclinical study
Read more